Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P810006/S115

Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo

Integra LifeSciences Corporation · Decision date Sep 18, 2026

MEDTECHLEDGER EXPLANATIONP810006/S115

What did the FDA decide?

P810006/S115 is a 30-Day Notice for the Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo, listed under product code LMF (absorbable hemostatic agent, collagen based) with Integra LifeSciences Corporation as applicant. The stated change is installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system, categorized as a process change involving manufacturer, sterilizer, packager, or supplier. The FDA database records the decision as OK30, dated 2026-09-18.

The identifier links this action to the original PMA P810006 as supplement S115, so it concerns that existing approval rather than a new approval of the whole system. The supplied statement does not specify which manufacturing site, what qualification criteria were used, or any resulting product or water-quality data, and it reports a purpose rather than demonstrating safety or clinical effectiveness. No new indication, trial, or clinical use is stated in the record.

FDA approval order statement

installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Sep 18, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P810006/S115
Regulatory pathway
PMA supplement
Product code
LMF
Decision code
OK30
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, collagen based.

Product code
LMF
FDA device class
3

For the original device and its historical approval scope, see PMA P810006. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P810006/S115 received

    Application receipt date recorded by FDA.

  2. P810006/S115 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P810006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P810006

Product / regulatory recordCompanyPathwayDecision dateSource
COLLASTATP810006
Integra LifeSciences CorporationPMA approvalDec 10, 1981FDA

Explore the linked device profile

Other records with product code LMF

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integra LifeSciences Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
311 Enterprise Dr., Planisboro, NJ, 08536

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records